The NHS will now fund fampridine, a drug that restores walking ability for people with multiple sclerosis by boosting nerve signals in the spinal cord. Up to 5,000 eligible patients across England stand to benefit from the treatment.
Fampridine works by unblocking potassium channels in damaged nerve fibers, allowing electrical signals to transmit more effectively. For MS patients whose mobility has been compromised by nerve damage, the drug can meaningfully improve walking speed and function. Clinical trials demonstrated that roughly one-third of patients who took fampridine experienced a measurable improvement in walking capacity.
The NHS England decision comes after the drug's manufacturer, Biogen, struck a new pricing agreement with the health service. The treatment had previously been available only through private purchase, placing it out of reach for most patients. The new arrangement makes fampridine accessible through the standard NHS pathway, removing a significant financial barrier for those with progressive or relapsing-remitting MS forms.
Multiple sclerosis affects approximately 130,000 people in the UK. The disease damages the protective coating around nerve fibers, progressively limiting mobility and independence. Walking difficulties rank among the most disabling symptoms, directly affecting quality of life and employment prospects. Fampridine represents a rare pharmacological intervention specifically targeting this core symptom rather than simply managing inflammation or slowing disease progression.
Patient advocacy groups have described the approval as transformative. For individuals whose mobility has plateaued despite other MS treatments, fampridine offers a targeted solution that doesn't require ongoing disease-modifying therapy adjustments. The drug enters a therapeutic landscape where MS treatments primarily focus on slowing neurological decline rather than restoring lost function.
NHS implementation will follow established criteria determining which patients qualify based on walking disability severity and other clinical factors. The decision underscores growing recognition that MS management must address functional outcomes alongside disease activity.